title: Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate.
abstract: Most of the world's haemophilia population live in countries with developing or emerging economies. As such, they do not have access to viral inactivated clotting product. Many are treated with cryoprecipitate made from locally supplied blood. The rationale for using cryoprecipitate instead of viral inactivated products is based on an implicit belief that because blood banks can provide reasonably safe products by using modern testing procedures, transmission of HIV and other blood-borne viruses is rare. However, the risk of acquiring a blood-borne infection is cumulative, and haemophilia patients treated with cryoprecipitate or fresh-frozen plasma are exposed to hundreds or thousands of donors during their lifetime. The risk that an HIV-infected person will be a donor during the 'window period' is directly related to the incidence of HIV in the country where the donation occurs. To illustrate the extent of this problem, we devise a model for estimating the risk that a person with haemophilia will encounter HIV-contaminated cryoprecipitate as a function of years of treatment and the underlying incidence rate of HIV among blood donors. We apply the model to two countries with different incidence rates of HIV, Venezuela and the USA. Over a lifetime of treatment (60 years), the cumulative risk of HIV exposure for a person with haemophilia receiving monthly infusion of cryoprecipitate prepared from plasma of 15 donors is significant, 2% in the USA and 40% in Venezuela. Considering the cumulative risk for transmitting HIV to patients with haemophilia through cryoprecipitate treatment, medical care providers should carefully evaluate the use of cryoprecipitate in any but emergency conditions or when no virally inactivated products are available.
authors.affiliation: Hematologic Diseases Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
authors.forename: B L
authors.initials: BL
authors.lastname: Evatt
authors.forename: H
authors.initials: H
authors.lastname: Austin
authors.forename: G
authors.initials: G
authors.lastname: Leon
authors.forename: A
authors.initials: A
authors.lastname: Ruiz-Sáez
authors.forename: N
authors.initials: N
authors.lastname: De Bosch
mesh_terms: D001793:Blood Preservation; D003450:Cryoglobulins / Q000009:adverse effects; D015925:Cryopreservation; D015658:HIV Infections / Q000097:blood / Q000635:transmission; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D012307:Risk Factors; D065227:Transfusion Reaction
chemical_list: D003450:Cryoglobulins